Archive · 14 Aug 2025
Weight Loss Drugs Linked to Slight Eye Problem Risk
Drugs like Ozempic and Wegovy, used for diabetes and weight loss, may slightly raise the chances of rare eye problems.
These drugs, known as GLP-1 agonists, can increase the risk of NAION, a condition that suddenly causes vision loss.
If you take these medicines, there's a very small chance of an 'eye stroke'.
People with diabetes are already at higher risk.
Doctors should talk about this risk when prescribing the drugs, and you should get regular eye checkups.
GLP-1 agonists like semaglutide and tirzepatide are used for diabetes and weight loss.
Studies indicate a small increased risk of serious eye conditions with these drugs.
Non-arteritic anterior ischaemic optic neuropathy (NAION), or 'eye stroke', is a potential risk.
People with diabetes are at increased risk of NAION.
Doctors should discuss NAION risks and patients should seek immediate medical attention for sudden vision loss.
- Who
- People taking GLP-1 agonists like semaglutide and tirzepatide.
- What
- GLP-1 agonists are linked to increased risk of eye conditions.
- When
- Studies are ongoing.
- Where
- Studies have analyzed data related to eye health.
- Why
- To assess the impact of the drugs on eye health.
Potential Risks
Overall Benefits
Risk vs. Benefit
Potential Risks
GLP-1 drugs slightly increase risks of eye problems.
Overall Benefits
The benefits of the drugs are significant despite the slight increase in risks.
- Drugs Mentioned
- Semaglutide, tirzepatide (Ozempic, Wegovy, Mounjaro)
- Eye Conditions
- NAION, Diabetic Retinopathy
- Risk of NAION
- Increased slightly
- NAION Side Effect
- Very rare (1 in 10,000)
